BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Stem Cell Product Launches, Acquisitions, Clinical Trials, and More
Stem Cell Product Launches, Acquisitions, Clinical Trials, and More

Stem Cell Product Launches, Acquisitions, Clinical Trials, and More

July 25, 2016 By Cade Hildreth (CEO) Leave a Comment

This week was a busy and active week within the stem cell industry, as evidenced by our coverage of stem cell markets below. I am excited to share with you.

Discover class-defining bioproduction tools.

Check it out and let me know what you think?


bitbio

Facilitating the Use of MSCs for Regenerative Medicine Applications through Serum-Free, Xeno-Free Differentiation

To facilitate improved culture conditions for MSCs in research and therapeutic applications, Biological Industries has launched novel serum-free and xeno-free hMSC differentiation kits. The launch represents a major advance within the MSC sector, because it creates a reproducible, contaminant-free environment for clinical-grade culture of human MSCs. BI’s serum-free and xeno-free kits are designed to be user-friendly with all necessary ingredients included, offering a complete system for multipotency evaluation of hMSCs and reliable induction of hMSCs into adipocytes, chondrocytes and osteoblasts/osteocytes.

Pluristyx

Investing in Cures for Cancer: GE Poised to Lead Industrialization of Cell Therapy Industry with Acquisition of Biosafe Group SA

GE Healthcare has acquired Biosafe Group SA, a supplier of integrated cell bioprocessing systems for the rapidly growing cell therapy and regenerative medicine industry for an undisclosed sum. The acquisition of Biosafe expands GE Healthcare’s end-to-end ecosystem of products, solutions and services for cell therapy customers, and expands GE’s technology reach to a number of new cell and therapy types.

NiCord® to Introduce Paradigm Shift to HSCT? Has Potential to Provide Transplantation Option To Nearly All In Need

iPSC-derived cardiomyocte therapy

Gamida Cell’s lead product, NiCord®, offers patients in need of HSCT an alternative to the existing approach of bone marrow transplant by using ex vivo expansion of cord blood. NiCord® has an orphan drug designation. NiCord®, CordIn™ and other products under development by Gamida Cell, all utilize the company’s proprietary NAM platform technology to expand cells while preserving, and surprisingly, even enhancing their functionality.

Landmark Stem Cell Clinical Trial Testing Escalating Doses of AST-OPC1 (Oligodendrocyte Progenitors)

Santa Clara Valley Medical Center is a site in the AST-OPC1 SCiSTAR Phase 1/2a clinical trial in complete cervical spinal cord injury, which is being sponsored by BioTime, Inc. (NYSE MKT: BTX) subsidiary Asterias Biotherapeutics (NYSE MKT: AST). The clinical trial will test the safety of three varying doses of AST-OPC1, which are oligodendrocyte progenitors that have the capacity to differentiate into a variety of brain cells. The study is funded in part by a $14.3 million grant from CIRM.

Interview with Paul Wotton, Current Board Member of Cynata Therapeutics and Previous President/CEO of Ocata Therapeutics

Dr. Paul Wotton joined the Board of Directors for Cynata Therapeutics (ASX: CYP) in June 2016. Cynata is an Australian company that is developing a therapeutic stem cell platform technology originating from the University of Wisconsin-Madison that utilizes iPSCs are starting material for generating nearly unlimited quantities of MSCs. Dr. Wotton was previously President and CEO of Ocata Therapeutics, joining the company in July 2014 and managing it through an all-cash take-over by Atellas Pharma valued at $379 million.

Mesenchymal Stem Cells – Advances & Applications [Global Strategic Report]

You should check out this 250-page global strategic report because: 1) MSC scientific publications have increased for 26 years straight, 2) MSCs are more frequently cited than any other stem cell type within the scientific literature, and 3) Google Trend data shows MSC searches to be approximately twice as common as the next most common adult stem cell type. The market for MSCs is growing. Are you informed about market opportunities and ready to act on them now?

About BioInformant

BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Vogue Magazine, and more. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.

Rate this post

Filed Under: Stem Cells Tagged With: cynata therapeutics, GE Healthcare, NiCord, regenerative medicine, stem cell, stem cell market

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Cord Blood Market Segmentation

Cord Blood Market Segmentation – Biobanking, HSCT, Cellular Therapy, Genetic Manipulation, & Research Tools

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.